The disclosure provides methods that facilitate disease management by providing for early detection of metabolic changes that differentiate critically ill-COVID-19 patients under mechanical ventilation at the intensive care unit (ICU) who are likely to exhibit faster recovery.

A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.

A blood flow stimulator may help encourage blood flow in a limb of a patient. The blood flow stimulator may include a housing configured for sealing about the limb of the patient. The housing may include a sealable volume, and the sealable volume may receive the limb of the patient. The blood flow stimulator may include a seal, and the seal may be coupled with the housing. The seal may engage with at least a portion of the limb, for instance to segregate the sealable volume from a surrounding environment of the blood flow stimulator. The blood flow stimulator may include a conduit extending through the housing. The conduit mat help provide access to the sealable volume, for instance from the surrounding environment. In some examples, an adjustable stent is utilized to enhance blood flow within vasculature of a patient. A stent operator may change a size of the stent.

A method for determining the dry weight of a patient after dialysis therapy, wherein the patient's blood volume is monitored and blood volume values are output. The blood volume values are recorded and evaluated for a predetermined period of time after reaching an ultrafiltration volume appropriately predetermined for the patient, wherein the dry weight of the patient then is determined on the basis of the rate of change of the blood volume during the predetermined period of time.

A blood pump including a housing having an inflow tube defining a major axis spanning through the inflow tube and a flow path spanning along the major axis, a rotor disposed within the inflow tube, the rotor and the inflow tube defining a gap therebetween, a stator surrounding the inflow tube and the rotor, and the housing defining an access conduit spanning through the inflow tube and the stator transverse to the major axis, the access conduit being in communication with the gap.

A method of treating a human subject which is effected by inhalation of gaseous nitric oxide, the method comprising a first treatment period comprising administering gNO by inhalation over a period of about at least 5 days, wherein the first treatment period is followed by a second treatment period comprising administering gNO by inhalation over a period of at least 3 months. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract.

An extracorporeal photopheresis system includes a separator with a disposable fluid circuit including a treatment container, an irradiation device configured to treat the contents of the treatment container, and a controller configured to control the system to perform a procedure including drawing anticoagulated whole blood into the fluid circuit from a blood source and returning to the blood source a treated target cell component, a portion of a red blood cell component remaining in the fluid circuit, and/or a portion of a plasma component remaining in the fluid circuit. The controller is further configured to estimate an end-of-procedure fluid balance estimated based on manual or automatic inputs including a patient body weight associated with the blood source and a total blood volume of the blood source, indicate the fluid balance to an operator, and receive one or more changes that affect the fluid balance after indicating the fluid balance.

Systems and method for verifying the timely placement of a container of biolocal cells or fluid within a treatment chamber of a biological fluid treating device are disclosed. The systems and methods utilize a sensor that detects the presence of a container at an appropriate and pre-determined time and, optionally, detects the weight of the container and cells.

The present disclosure relates to a method for determining or recommending a time point for measuring a patient's pressure readings during a blood treatment session. The method encompasses monitoring the ultrafiltration rate with which the patient's blood is treated, a relative blood volume, and/or a sodium concentration or a change in any of these, for the existence of, or meeting any pre-determined criterion for the ultrafiltration, the relative blood volume, and/or the sodium concentration, or the change thereto. Furthermore, the method encompasses transmitting a signal to a blood pressure measuring device when the pre-determined criterion for the ultrafiltration rate, the relative blood volume, and/or the sodium concentration or the change thereto is met.

A dialysis device (100) comprises: a dialyzer for exchange of substances between a blood flow and a dialysate flow in a dialysis area (106) of the dialyzer, wherein the dialyzer comprises a dialyzer membrane (110) for passing toxins in the blood flow to the dialysate flow through pores (112) of the dialyzer membrane (110); and a capacitively coupled generator (120) for generating electromagnetic fields in the dialysis area (106) for loosening electrostatic bonds between toxins and proteins in the blood flow, wherein the generator (120) is capacitively coupled to the blood flow and to the dialysate flow on opposite sides of the dialyzer membrane, and wherein the dialysate membrane (110) is formed of a material having lower conductance than blood and dialysate such that a large electromagnetic field strength is provided across the pores (112) of the dialyzer membrane (110).